Iridex (IRIX) Q3 2026 earnings review

Iridex cuts its sales plan, though U.S. prices lift margins

Iridex, a maker of eye-surgery lasers and disposable probes, saw sales drop across every product line while U.S. pricing lifted its profit margin. Third-quarter revenue fell 19% from a year ago to $10 million as overseas distributors worked through stockpiled glaucoma probes and retina laser demand weakened in Europe and Asia. Chief executive Patrick Mercer cut the full-year sales plan by $5 million, and by our math the new outlook points to a 15% sales decline in the fourth quarter.

At a glance
Revenue$10.2M -19% from a year ago
Gross margin, excluding one-offs42.4% 38.7% a year ago
Cyclo G6 probes sold11,900 -20% from a year ago
Full-year revenue outlookCut $5M middle of the range: -11% from 2025

⚖️ Verdict: 🔴 Bearish

The story got worse because the long-standing risk of a full-year sales miss arrived and cash fell to $3.7 million. Glaucoma probe shipments reversed from growth to a 20% drop as earlier distributor stockpiling unwound, while safety-stock inventory for the headquarters move absorbed $2 million of cash. One positive: underlying gross margin rose nearly 4 percentage points on higher U.S. probe prices and the San Jose headquarters move finished on schedule.

The question now is whether unwinding that extra factory inventory can stop the cash drain and whether overseas probe orders rebound once distributor stocks clear. Either fourth-quarter sales and inventory drawdown restore cash, or a smaller revenue base leaves the balance sheet stretched ahead of a 2028 debt maturity. Fourth-quarter cash, inventory and probe volumes will settle it.

🐂 Bull Case

🟢 fading MARGIN

U.S. Sales and Prices Lifted Gross Margin

Iridex makes medical lasers and single-use eye probes, and its profitability has suffered from manufacturing costs and tariffs for a year. In the third quarter, reported gross margin jumped 10.2 percentage points from a year ago to 42.4%, because cost of revenues — the cost of making its products — dropped from 67.9% of sales to 57.6%.

Last year's third quarter included a one-time $0.8 million inventory write-off for moving production to outside factories. Excluding that charge, underlying gross margin in the prior year was 38.7%, so the like-for-like improvement was 3.7 percentage points. The laser maker attributed the gain to "more favorable geographic mix and sustained pricing discipline" as higher-priced U.S. glaucoma probe sales offset lower international distributor orders.

What to watch: fourth-quarter gross margin when international distributor shipments resume. If overseas orders rebound and pull gross margin back below 38%, this quarter's improvement came from temporary regional mix rather than lasting factory savings.

🟢 strengthening MARGIN

Headquarters Move Finishes and Cuts Costs

Chief executive Patrick Mercer has spent the past year cutting overhead and moving operations to cheaper locations. This quarter the eye-care company completed its headquarters relocation to San Jose, a move it expects to save about $600,000 a year. It also held third-quarter operating expenses — research, sales and overhead — steady at $5.5 million despite $141,000 in severance and shareholder-meeting costs.

With the building move finished, Iridex expects the shift of major product manufacturing to outside contractors to be "the next significant driver of margin expansion through 2027". The company kept its full-year operating expense plan excluding non-cash items at $19.0 million to $19.5 million, showing cost control is on track even as revenue falls.

What to watch: the initial 2027 operating expense and gross margin targets on the fourth-quarter call. They will show how much the San Jose move and outside factories lower the quarterly break-even point.

🐻 Bear Case

🔴🔴 strengthening GROWTH

Full-Year Revenue Plan Cut by $5 Million

For two quarters Iridex maintained its $51 million to $53 million annual sales forecast, which required an unusually strong second half despite zero sales in the Middle East. Third-quarter revenue fell 19% from a year ago to $10.2 million, forcing the company to cut its full-year outlook to between $46 million and $48 million.

  • Retina product revenue: $5.1 million, down 24% from $6.7 million a year ago
  • Other service and royalty revenue: $1.9 million, down 14% from $2.2 million
  • Fourth-quarter revenue implied by the new outlook: $12.5 million at the middle of the range, down 15% from a year ago by our math

Mercer blamed "weaker than anticipated customer demand in Europe and Asia coupled with order delays late in the quarter as distributors worked through probe inventory and ongoing regulatory challenges". Because the ophthalmic group expects third-quarter trends to continue, the lower outlook confirms that international retina weakness is not rebounding this year.

What to watch: fourth-quarter revenue against the $11.5 million to $13.5 million range implied by the full-year plan. A finish near the bottom would mean international retina demand is still shrinking entering 2027.

🔴 fading PRODUCT

Glaucoma Probe Volumes Reversed on Stockpiling Unwind

The Cyclo G6 product line, which uses a laser console and single-use probes to treat glaucoma, had been Iridex's sole growth driver, with probe volumes rising in five of the prior six quarters. In the third quarter, Cyclo G6 revenue fell 9% from a year ago to $3.2 million as probe shipments dropped 20% to 11,900 units and console sales slipped from 30 to 28.

International distributors had bought extra probes earlier in the year ahead of the headquarters move and chose to sell down that stock in the third quarter, while U.S. glaucoma sales and probe prices rose. By our math, Cyclo G6 family revenue per probe sold reached $269, up from $235 a year ago, supporting the U.S. pricing story even as overseas volume paused.

What to watch: fourth-quarter Cyclo G6 probe units once distributor inventory normalizes. A rebound above 15,000 units would show underlying doctor usage remains intact after the restocking swing.

🔴🔴 strengthening CASH contradicts narrative

Safety Stock Built Inventory and Drained Cash

Iridex previously targeted positive operating cash flow for 2026 while building safety-stock inventory to prevent supply gaps during its factory and headquarters move. This quarter the release dropped the full-year cash flow target and stated that "Cash utilization is expected to decrease significantly with stronger sales and consumption of the safety stock inventory".

Cash and cash equivalents fell by $1.0 million during the quarter to $3.7 million, as inventories jumped by $2.0 million to $11.8 million — up 49% since the start of the year. The cash drain stayed at $1.0 million only because accounts receivable dropped by $2.3 million on lower sales and accounts payable rose by $0.3 million, which are working-capital tailwinds that reverse when sales recover.

What to watch: fourth-quarter inventory and cash balances on the year-end balance sheet. If inventory does not fall below $10 million, cash will stay tight ahead of the $3.8 million convertible note maturing in 2028.

🔴 persistent DISCLOSURE

Risks this quarter didn't answer

Four standing risks from prior filings received no update in the third-quarter earnings release.

  • European approval for the Pascal retina laser: previously expected in the first half of 2027 after regulatory delays; the release gave no timeline update.
  • Refinancing of the $3.8 million convertible note: matures in March 2028 against $3.7 million of cash on hand; the quarterly filing will show any new financing terms.
  • Reliance on Topcon: the exclusive overseas distributor accounts for about a third of sales and most deferred revenue; the quarterly filing will disclose third-quarter Topcon sales.
  • Nasdaq minimum bid compliance: incurred $152,000 of compliance costs last year; the release included no update on listing status.

👓 Other Themes

new MACRO

Strategic Review Reprioritizes Product Lines

Alongside weak demand in Europe and Asia and excluded Middle East sales, Mercer announced that Iridex is "deep into a strategic review of our product lines, and as part of that work we are reprioritizing our resources toward our most profitable opportunities". The company gave no details on which products could lose funding, promising only to enter 2027 with a lower cost base.

💲 Other KPIs

Total deferred revenue (26Q3) $7.92 million
⇘ decelerating

Combined short-term and long-term deferred revenue — cash collected upfront for service contracts and distribution rights not yet recognized as sales — fell 15.9% from a year ago and shrank by $307,000 from last quarter. The balance has declined every quarter this year as long-term exclusivity fees amortize faster than new service contracts are added.

Accounts receivable (26Q3) $4.78 million
⇘ decelerating

Uncollected customer bills dropped 32.6% from $7.09 million last quarter and are down 50.0% from $9.55 million at the start of the year. Collecting prior-quarter bills while new third-quarter shipments slowed generated $2.31 million in working capital, which offset the $2.01 million spent building factory inventory.

Diluted share count (26Q3) 17.59 million
⇗ accelerating

Weighted average diluted shares rose 3.4% from 17.01 million a year ago and increased by 175,000 shares from the second quarter. The steady increase comes from employee stock compensation and interest on the convertible note paid in common shares.

🔮 Guidance

FY26 Revenue $46.0–48.0 million
🠇 cut from $51.0–53.0 million
⇘ decelerating

Cut. Management lowered the full-year sales plan by $5 million after holding it unchanged for two quarters, which puts annual sales down 10.8% from 2025 at the middle of the range. By our math, that leaves $11.5 million to $13.5 million for the fourth quarter — up 23% from a weak third quarter on normal year-end hospital buying, but down 15% from a year ago.

FY26 Operating expenses, excluding one-offs $19.0–19.5 million
🠆 unchanged from $19.0–19.5 million
⇒ stable

Unchanged. The plan still calls for full-year operating expenses excluding depreciation, amortization and stock compensation to fall about 1.4% from 2025 at the middle of the range. Through nine months, the medical device maker has spent $14.26 million on this basis, leaving $4.99 million for the fourth quarter by our math, compared with $4.86 million in the third quarter.

❓ Key Questions

Which products face cuts in the strategic review?

Mercer said Iridex is reprioritizing resources toward its most profitable opportunities for 2027. Investors need to know whether the company will discontinue specific retina consoles and how much revenue or inventory write-offs that exit would involve.

Is the full-year positive operating cash flow target dead?

Prior quarters promised positive operating cash flow for 2026, but the third-quarter release promised only that fourth-quarter cash burn would decrease. With $3.7 million in cash and $11.8 million in inventory, the exact year-end cash floor matters.

How much did U.S. revenue grow in the third quarter?

The release highlighted growth in U.S. glaucoma sales and higher U.S. probe prices, but gave no total U.S. dollar figure. Last quarter U.S. sales fell 11% in the quarterly filing despite similar positive commentary.

When will European regulators approve the Pascal laser?

Management previously expected European certification for its Pascal retina product in the first half of 2027. With Europe and Asia demand weak and regulatory challenges cited again in the third quarter, any further slip would delay a retina recovery.